Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Publication year range
1.
Mol Cell Endocrinol ; 592: 112318, 2024 Oct 01.
Article in English | MEDLINE | ID: mdl-38908427

ABSTRACT

INTRODUCTION: AMPK (AMP-activated protein kinase) is an enzyme that acts as a metabolic sensor and regulates multiple pathways via phosphorylating proteins in metabolic and proliferative pathways. The aim of this work was to study the activated cellular AMPK (phosphorylated-AMPK at Thr172, pAMPK) levels in pituitary tumor samples from patients with sporadic and familial acromegaly, as well as in samples from normal human pituitary gland. METHODS: We studied pituitary adenoma tissue from patients with sporadic somatotroph adenomas, familial acromegaly with heterozygote germline variants in the aryl hydrocarbon receptor interacting protein (AIP) gene (p.Q164*, p.R304* and p.F269_H275dup) and autopsy from normal pituitary glands without structural alterations. RESULTS: Cellular levels of pAMPK were significantly higher in patients with sporadic acromegaly compared to normal pituitary glands (p < 0.0001). Tissues samples from patients with germline AIP mutations also showed higher cellular levels of pAMPK compared to normal pituitary glands. We did not observe a significant difference in cellular levels of pAMPK according to the cytokeratin (CAM5.2) pattern (sparsely or densely granulated) for tumor samples of sporadic acromegaly. CONCLUSION: Our data show, for the first time in human cells, an increase of cellular levels of pAMPK in sporadic somatotropinomas, regardless of cytokeratin pattern, as well as in GH-secreting adenomas from patients with germline AIP mutations.


Subject(s)
AMP-Activated Protein Kinases , Adenoma , Growth Hormone-Secreting Pituitary Adenoma , Humans , AMP-Activated Protein Kinases/metabolism , AMP-Activated Protein Kinases/genetics , Male , Growth Hormone-Secreting Pituitary Adenoma/genetics , Growth Hormone-Secreting Pituitary Adenoma/metabolism , Growth Hormone-Secreting Pituitary Adenoma/pathology , Female , Middle Aged , Adult , Adenoma/genetics , Adenoma/pathology , Adenoma/metabolism , Adenoma/enzymology , Acromegaly/genetics , Acromegaly/pathology , Acromegaly/metabolism , Intracellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins/metabolism , Aged , Pituitary Neoplasms/genetics , Pituitary Neoplasms/pathology , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/enzymology , Phosphorylation , Pituitary Gland/metabolism , Pituitary Gland/pathology , Gene Expression Regulation, Neoplastic
2.
Neuropathology ; 35(1): 16-23, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25410472

ABSTRACT

Estrogen has been shown to play an important role in pituitary tumor pathogenesis. In humans, this biosynthesis is mediated by aromatase, an enzyme that converts androgens to estrogens. Just a few studies about aromatase expression in human pituitary gland, both in normal and pathological ones, are found in the literature. This study aimed to assess aromatase enzyme expression in human pituitary adenomas and associate it with gender, tumor size and tumor subtype. We conducted a cross-sectional study, reviewed clinical data and surgical specimens of consecutive 65 patients (35 women and 30 men) with anatomopathologic diagnosis of pituitary adenoma who underwent adenomectomy at a neurosurgical referral center in southern Brazil. Immunohistochemistry was performed to assess aromatase expression and define tumor subtype, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to estimate aromatase gene expression. Mean patient age was 45.6 (±13.3) years (range, 18 to 73 years), 86.2% of our samples were macroadenomas while 13.8% were classified as microadenomas. Based on clinical and immunohistochemical data, 23 (35.4%) patients had non-functioning adenomas, 19 (29.2%) had somatotroph adenomas (acromegaly), 12 (18.5%) had lactotroph adenomas (hyperprolactinemic syndrome), and 11 (16.9%) had corticotroph adenomas (Cushing's disease). Immunohistochemical analysis was performed in 59 cases, and 58 (98.3%) showed no aromatase expression. Quantification by qRT-PCR was performed in 43 samples, and 36 (83.7%) revealed no gene expression. Among tumor specimens examined by both techniques (37 cases), 30 showed no gene or protein expression (concordance index, 0.81). It is possible to mention that aromatase expression was lost in most pituitary adenomas, regardless of gender, tumor subtype, or tumor size.


Subject(s)
Adenoma/enzymology , Aromatase/metabolism , Pituitary Neoplasms/enzymology , Adenoma/classification , Adenoma/pathology , Adolescent , Adult , Aged , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Pituitary ACTH Hypersecretion/enzymology , Pituitary Neoplasms/classification , Pituitary Neoplasms/pathology , Sex Factors , Young Adult
3.
Endocrine ; 41(3): 532-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22207295

ABSTRACT

Type 1 (D1) and 2 (D2) iodothyronine deiodinases are selenocysteine-containing enzymes that catalyze the deiodination of T4 to T3 in the thyroid and in peripheral tissues. Despite their importance to the plasma T3 pool in human beings, there are few studies about their behavior in human thyroids. In order to better understand iodothyronine deiodinase regulation in the thyroid gland, we studied thyroid tissue samples from follicular adenoma (AD, n = 5), toxic diffuse goiter (TDG, n = 6), nontoxic multinodular goiter (NMG, n = 40), papillary thyroid carcinoma (PTC, n = 8), and surrounding normal tissues (NT, n = 7) from 36 patients submitted to elective thyroidectomy. D1 and D2 activities were determined by quantification of the radioiodine released by ¹²5I-rT3 or ¹²5I-T4 under standardized conditions, and expressed as pmol rT3 deiodinated per minute and mg protein (pmol rT3 min⁻¹ mg⁻¹ ptn) and fmol T4 deiodinated per minute and mg protein (fmol T4 min⁻¹ mg⁻¹ ptn), respectively. D1 activity detected in TDG and AD tissues were significantly higher than in NT, PTC or NMG samples. D2 activity was also significantly higher in TDG and AD samples than in PTC, NMG, or NT. There was great variability in D1 and D2 enzymatic activities from distinct patients as well as from different areas from the same goiter. There was a positive correlation (P < 0,0001, r = 0.4942) between D1 and D2 activities when all samples were taken into account, suggesting that-in the thyroid-these two iodothyronine deiodinases may have related regulatory mechanisms, even if conditioned by other as yet unknown factors.


Subject(s)
Goiter, Nodular/enzymology , Iodide Peroxidase/metabolism , Neoplasm Proteins/metabolism , Thyroid Gland/enzymology , Thyroid Neoplasms/enzymology , Adenoma/enzymology , Adenoma/pathology , Adolescent , Adult , Aged , Carcinoma/enzymology , Carcinoma/pathology , Carcinoma, Papillary , Female , Goiter/enzymology , Goiter/pathology , Goiter, Nodular/pathology , Humans , Isoenzymes/metabolism , Kinetics , Male , Middle Aged , Neoplasm Staging , Organ Size , Thyroid Cancer, Papillary , Thyroid Gland/pathology , Thyroid Neoplasms/pathology , Young Adult , Iodothyronine Deiodinase Type II
4.
Int J Exp Pathol ; 85(4): 213-22, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15312126

ABSTRACT

Heme oxygenase (HO) breaks down the pro-oxidant heme into carbon monoxide, iron and the antioxidant biliverdin. The isoform HO-1 plays an effective role to counteract oxidative damage and to control inflammation. Prolonged cellular damage due to chronic inflammation is one of the reasons leading to the development of tumours. The aim of this work was to investigate HO-1 expression and localization along the different stages of chemically induced hepatocarcinogenesis (HCC) and the occurring morphological changes. To provoke sustained oxidative stress and chronic inflammation, CF1 mice received dietary p-dimethylaminoazobenzene (DAB, 0.5%, w/w) during a whole period of 14 months. HO-1 expression increased along the experimental trial in morphologically normal hepatocytes in DAB-treated animals. HO-1 expression diminished in altered hepatic foci (AHF) and oval cells and early preneoplastic lesions. Otherwise, marked HO-1 overexpression was detected in Kupffer cells and macrophages surrounding necrotic and nodular areas. Adenomas showed decreased HO-1 immunostaining. In hepatocellular carcinomas, an inverse relationship was found between the immunohistochemical expression of HO-1 and the degree of tumour differentiation, being negative in poorly differentiated tumours. In our experimental model, down modulation of HO-1 expression correlated with malignancy progression. Thus, our data point to activation of HO-1 as a potential therapeutic tool.


Subject(s)
Heme Oxygenase (Decyclizing)/metabolism , Liver Neoplasms/enzymology , Precancerous Conditions/enzymology , Adenoma/chemically induced , Adenoma/enzymology , Adenoma/pathology , Animals , Blotting, Western , Carcinoma, Hepatocellular/chemically induced , Carcinoma, Hepatocellular/enzymology , Carcinoma, Hepatocellular/pathology , Disease Progression , Heme Oxygenase-1 , Hepatocytes/enzymology , Immunoenzyme Techniques , Liver/pathology , Liver Neoplasms/chemically induced , Liver Neoplasms/pathology , Macrophages/enzymology , Macrophages/pathology , Male , Membrane Proteins , Mice , Mice, Inbred Strains , Necrosis , Precancerous Conditions/chemically induced , Precancerous Conditions/pathology , p-Dimethylaminoazobenzene
5.
J Clin Endocrinol Metab ; 79(1): 39-44, 1994 Jul.
Article in English | MEDLINE | ID: mdl-8027249

ABSTRACT

Several biochemical and functional modifications demonstrated in goitrous tissues could reflect the effect of goitrogenic factors. Growth-enhancing agents, including TSH itself, have been involved in goitrogenesis. To study comparatively the variation patterns of some TSH-dependent enzymes within single goitrous tissues, we measured the activities of peroxidase (TPO), NADPH-cytochrome-c (cyt-c) reductase, and monoamine oxidase (MAO) in tissues from cold follicular adenoma and multinodular goiter. Iodide transport and organification were also evaluated. Perinodular and necropsy tissues were used as controls. The mean TPO activity measured by guaiacol as well as triiodide assays was significantly increased in multinodular goiter, whereas a nonsignificant increment was observed in cold adenoma. NADPH-cyt-c reductase and MAO were markedly increased in the two types of pathological tissues. The individual activities of the three enzymes showed dissimilar modifications within single samples and among different tissues. There was no correlation in the activities of the enzymes within single specimens from cold adenoma and multinodular goiter, except for MAO and NADPH-cyt-c reductase in multinodular goiter, for which a significant correlation was obtained. In this tissue, MAO and TPO measured by guaiacol assay were weakly correlated. TPO activity evaluated by guaiacol oxidation was correlated with that measured by triiodide formation in cold adenoma, but not in multinodular goiter. The mean iodide organification values assayed by iodotyrosine formation in the absence of exogenous H2O2 in particulate fractions from cold adenoma and multinodular goiter were within the normal range. A reduced iodide transport, evaluated as the thyroid/medium ratio, was observed in slices from these tissues. The dissociation of the three enzyme activities in single specimens from cold adenoma and multinodular goiter along with the reduced iodide transport in these tissues support the hypothesis that factors other than TSH or with TSH-like effects could be involved in the abnormal thyroid growth.


Subject(s)
Adenoma/enzymology , Goiter, Nodular/enzymology , Iodides/metabolism , Thyroid Neoplasms/enzymology , Thyrotropin/pharmacology , Biological Transport , DNA/metabolism , Humans , Iodide Peroxidase/metabolism , Monoamine Oxidase/metabolism , NADPH-Ferrihemoprotein Reductase/metabolism , Thyroid Gland/enzymology
6.
Clin Endocrinol (Oxf) ; 30(6): 681-6, 1989 Jun.
Article in English | MEDLINE | ID: mdl-2556223

ABSTRACT

Monoamine oxidase (MAO) activity and its forms were measured in normal human thyroid glands (39 samples from necropsy and four from perinodular tissues) and in pathological thyroid glands (13 multinodular goitres, three carcinomas, seven chronic thyroiditis, five Graves' disease and seven follicular, seven foetal and five embryonal adenomas). MAO activity in carcinomas was lower than in normal perinodular thyroid control tissue; in Graves' disease, foetal and embryonal adenomas it was significantly higher than in the normal control. The use of clorgyline (a selective MAO A inhibitor) and deprenyl (selective MAO B inhibitor) allowed estimation of the relative proportion of MAO forms. A high proportion of MAO A (more than 90%) was observed, both in normal and in pathological thyroid tissues. Changes in total thyroid MAO activity, but not in its forms, were found in different pathologies of the thyroid gland.


Subject(s)
Monoamine Oxidase/metabolism , Thyroid Diseases/enzymology , Thyroid Gland/enzymology , Adenoma/enzymology , Carcinoma/enzymology , Clorgyline/pharmacology , Humans , Monoamine Oxidase Inhibitors/pharmacology , Neoplasms, Germ Cell and Embryonal/enzymology , Reference Values , Selegiline/pharmacology , Thyroid Neoplasms/enzymology
8.
Acta Gastroenterol Latinoam ; 11(1): 125-32, 1981.
Article in Spanish | MEDLINE | ID: mdl-6275651

ABSTRACT

This paper was designed to study experimentally in rats hepatic and serum pseudocholinesterase, (CHE), and its isoenzyme activity, and also to analyze its behavior in acute hepatitis, cirrhosis and primary and secondary hepatic tumours. Five isoenzymes in rat liver homogenates and 4 to 5 in rat serum were found. In normal human serum 4 to 5 CHE-isoenzymes were recognized. Cuali and quantitative decreases in all serum CHE isoenzymes were found in all patients with severe liver disease. Isoenzyme No. 1 decreased significatively in cirrhotics, showing a double peak inscription. Isoenzyme No. 5 was elevated in the three patients with hepatoma.


Subject(s)
Butyrylcholinesterase/blood , Cholinesterases/blood , Isoenzymes/blood , Liver Diseases/enzymology , Liver Neoplasms/enzymology , Liver/enzymology , Adenoma/enzymology , Animals , Carcinoma, Hepatocellular/enzymology , Densitometry , Electrophoresis, Polyacrylamide Gel , Hepatitis/enzymology , Humans , Liver Cirrhosis/enzymology , Male , Rats
SELECTION OF CITATIONS
SEARCH DETAIL